Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:

NCT ID: NCT04560816 Completed - Healthy Clinical Trials

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

Start date: July 24, 2020
Phase: Phase 1
Study type: Interventional

This study will evaluate the effect of a supratherapeutic dose of ALXN1840 on the heart rate (HR)-corrected QT interval (QTc) in healthy adult participants. Moxifloxacin will be used as the active control.

NCT ID: NCT04559568 Completed - Healthy Clinical Trials

A Study of LY3522348 in Healthy Participants

Start date: October 15, 2020
Phase: Phase 1
Study type: Interventional

The main purpose of this study in healthy participants is to learn more about the safety of LY3522348 and any side effects that might be associated with it. Blood tests will be performed to check how much LY3522348 gets into the bloodstream and how long it takes the body to eliminate it. This study has two parts: Part A will last up to about six weeks and Part B will last up to about eight weeks for each participant.

NCT ID: NCT04558294 Completed - Healthy Clinical Trials

Effect of Ketanserin After LSD Administration

L-Ket
Start date: October 16, 2020
Phase: Phase 1
Study type: Interventional

LSD (lysergic acid diethylamide) is a serotonergic (5-HT) hallucinogen widely used for recreational and/or ethnomedical purposes. LSD is thought to induce its prototypical psychedelic effects primarily via stimulation of the 5-HT2A receptor. This study investigates whether an LSD experience can be attenuated and shortened using 5-HT2A receptor antagonist ketanserin administration after LSD once the psychedelic effects have established.

NCT ID: NCT04556526 Completed - Healthy Clinical Trials

A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women

INGABO
Start date: October 5, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is: a) to assess adverse maternal/fetal outcomes in pregnant women randomized to receive the 2- dose Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo [Group A]) and in control women (unvaccinated pregnant women [Group B]); and b) to assess adverse neonatal/infant outcomes in neonates/infants born to women randomized to receive the 2-dose Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo [Group A]) and in neonates/infants born to control women (unvaccinated during pregnancy [Group B]).

NCT ID: NCT04556110 Completed - Healthy Clinical Trials

A Study on the Bioequivalence of Perindopril Tert-butylamine Tablets Taken on After Meals in Healthy Subjects

Start date: November 20, 2018
Phase: Phase 1
Study type: Interventional

In order to evaluate the bioequivalence of the test preparation and reference preparation of perindopril tert-butylamine tablets after meal and their safety in Chinese adult healthy subjects.

NCT ID: NCT04556058 Completed - Healthy Clinical Trials

A Study on the Bioequivalence of Perindopril Tert-butylamine Tablets Taken on an Empty Stomach in Healthy Subjects

Start date: November 29, 2018
Phase: Phase 1
Study type: Interventional

In order to evaluate the bioequivalence of the test preparations and reference preparations of perindopril tert-butylamine tablets after meal and their safety in Chinese adult healthy subjects.

NCT ID: NCT04555954 Completed - Healthy Clinical Trials

Determining the Physical Activity Level of Healthy Adults During Pandemic

Start date: April 11, 2020
Phase:
Study type: Observational

Abstract Background: With Covid-19 pandemic, online education, remote and flexible working were introduced. Thus the process of stay-at-home began. Purpose: The aim of the study is to determine level of physical activity of healthy adults in the pandemic process. Methods: This is a descriptive survey study which was applied via internet. The physical activity level was evaluated with International Physical Activity Questionnaire Short Form. Healthy adults aged 18-65 years who live in Turkey were included in the study.

NCT ID: NCT04555850 Completed - Healthy Clinical Trials

A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers

Start date: July 30, 2018
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety, tolerance, pharmacokinetics and the potential immunological reaction of single intravenous recombinant human thymosin β4(NL005)or placebo 0.5, 2.0,5.0μg/kg in Chinese healthy volunteers.30 volunteers will be randomly assigned to one of three groups to receive either NL005 or placebo for 10 consecutive days.

NCT ID: NCT04555824 Completed - Healthy Clinical Trials

A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers

Start date: July 17, 2017
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety, tolerance, pharmacokinetics and the potential immunological reaction of single intravenous recombinant human thymosin β4(NL005)or placebo 0.05, 0.25, 0.5, 2, 5, 12.5, 25μg/kg in Chinese healthy volunteers. 54 volunteers will be randomized to receive NL005 or placebo for 7 cohorts,administered iv by iv push on Day 1.

NCT ID: NCT04555447 Completed - Healthy Clinical Trials

Gastrointestinal Tolerability to Agavins and Impact on Host-gut Microbiota-metabolism Interactions Modulation

Start date: March 22, 2019
Phase: N/A
Study type: Interventional

Agavins are branched neo-fructans and prebiotic fiber found in Agave plants. In preclinical studies, agavins have demonstrated an effect in reversing metabolic disorders associated to overweight and obesity through the modulation of gut microbiota activity and composition, showing their interesting potential in the context of high obesity and cardiovascular diseases prevalence in Mexican population. However, current information about gastrointestinal adaptation and effects of agavins intake in humans is scarce. We hypothesized that increasing amounts of agavins up to 12 g/day, will be well tolerated by healthy and obese adult participants, but with differences between these groups, modulating gut microbiota activity and structure differentially, as well as the metabolic status after a 5-week dose-escalation intervention.